Summary
Eli Lilly and Company reported a decrease in net sales and net income for the first quarter of 2002 compared to the prior year, primarily driven by the impact of generic competition for Prozac in the U.S. market. Despite the overall sales decline, the company experienced significant growth in key products such as Zyprexa, Humalog, Gemzar, and Evista, demonstrating continued strength in its growth portfolio. Looking ahead, Lilly expects a challenging second quarter but anticipates flat sales for the full year 2002 with earnings per share projected to be between $2.60 and $2.65, excluding unusual items. The company is also navigating regulatory hurdles related to manufacturing practices, which could impact the launch timeline of several new products, including Cialis.
Key Highlights
- 1Net sales decreased by 9% to $2.56 billion for Q1 2002 compared to $2.81 billion in Q1 2001, largely due to generic Prozac entry.
- 2Net income decreased by 22% to $629.2 million ($0.58 per share) in Q1 2002 from $806.8 million ($0.74 per share) in Q1 2001.
- 3Zyprexa sales showed strong growth, increasing 29% to $819.4 million worldwide.
- 4Excluding Prozac, worldwide sales increased by 9% and U.S. sales increased by 12%, highlighting the performance of other products.
- 5The company issued $500 million of 6% 10-year notes in March 2002, increasing total debt.
- 6Lilly is addressing FDA observations regarding manufacturing practices, which could affect the approval timelines for new products like Cialis, Zyprexa IntraMuscular, and Fortéo.
- 7The company repurchased approximately 725,000 shares in Q1 2002 as part of its $3 billion share repurchase program.